Acute treatment with agomelatine was associated with a statistically significant superiority over placebo of − 1.51 HRSD points (99 % Cl − 2.29 to − 0.73, nine studies).
Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for depression and anxiety but their superiority over placebo has been questioned, generating considerable debate among researchers and clinicians.